Erasca, Inc.

Erasca, Inc.verified

ERAS

Price:

$3.12

Market Cap:

$810.72M

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.[Read more]

Industry

Biotechnology

IPO Date

2021-07-16

Stock Exchange

NASDAQ

Ticker

ERAS

The PE Ratio as of July 2024 (TTM) for Erasca, Inc. (ERAS) is -3.71

According to Erasca, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.71. This represents a change of 38.28% compared to the average of -2.68 of the last 4 quarters.

Erasca, Inc. (ERAS) Historical PE Ratio (quarterly & annually)

How has ERAS PE Ratio performed in the past?

The mean historical PE Ratio of Erasca, Inc. over the last ten years is -44.44. The current -3.71 PE Ratio has changed 734.77% with respect to the historical average. Over the past ten years (40 quarters), ERAS's PE Ratio was at its highest in in the December 2022 quarter at -1.04. The PE Ratio was at its lowest in in the June 2020 quarter at -18.69.

Quarterly (TTM)
Annual

Average

-44.44

Median

-11.98

Minimum

-193.11

Maximum

-2.21

Erasca, Inc. (ERAS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Erasca, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 15.85%

Maximum Annual PE Ratio = -2.21

Minimum Annual Increase = -93.80%

Minimum Annual PE Ratio = -193.11

Quarterly (TTM)
Annual
YearPE RatioChange
2023-2.5615.85%
2022-2.21-82.14%
2021-12.363.20%
2020-11.98-93.80%

Erasca, Inc. (ERAS) Average PE Ratio

How has ERAS PE Ratio performed in the past?

The current PE Ratio of Erasca, Inc. (ERAS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.71

5-year avg

-44.44

10-year avg

-44.44

Erasca, Inc. (ERAS) PE Ratio vs. Peers

How is ERAS’s PE Ratio compared to its peers?

Erasca, Inc.’s PE Ratio is less than Century Therapeutics, Inc. (-1.11), less than NGM Biopharmaceuticals, Inc. (-0.91), greater than Keros Therapeutics, Inc. (-9.09), less than Monte Rosa Therapeutics, Inc. (-1.94), greater than Gracell Biotechnologies Inc. (-12.57), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Design Therapeutics, Inc. (-4.55), greater than Edgewise Therapeutics, Inc. (-17.49), less than C4 Therapeutics, Inc. (-3.16), greater than Mineralys Therapeutics, Inc. (-6.81), greater than Cullinan Oncology, Inc. (-6.64), greater than Sana Biotechnology, Inc. (-4.32), greater than Olema Pharmaceuticals, Inc. (-8.24), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.39), less than Relay Therapeutics, Inc. (-3.55), greater than Stoke Therapeutics, Inc. (-6.10), greater than Pliant Therapeutics, Inc. (-4.45), greater than Black Diamond Therapeutics, Inc. (-3.97), greater than Arvinas, Inc. (-5.80),

Build a custom stock screener for Erasca, Inc. (ERAS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Erasca, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Erasca, Inc. (ERAS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Erasca, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Erasca, Inc.'s PE Ratio?

How is the PE Ratio calculated for Erasca, Inc. (ERAS)?

What is the highest PE Ratio for Erasca, Inc. (ERAS)?

What is the 3-year average PE Ratio for Erasca, Inc. (ERAS)?

What is the 5-year average PE Ratio for Erasca, Inc. (ERAS)?

How does the current PE Ratio for Erasca, Inc. (ERAS) compare to its historical average?